Approximately 450,000 stroke cases are reported annually in Russia, making it a leading cause of mortality and disability. Up to 30% of these cases occur in the working-age population, yet standard imaging techniques often fail to detect structural changes during the critical first hours.

The primary danger lies in the gradual progression of chronic cerebral ischemia, which often remains asymptomatic and invisible to patients and standard screening methods. Unlike CT or MRI, which record damage that has already occurred, the NR2 biomarker identifies biochemical signs of ischemia and neuronal damage at the pre-hospital stage.